| Variables | sVCAM-1 levels (ng/mL) | p-value | |||
| N | Mean (SD) | Median | Range | ||
| Sex |
|
|
|
| 0.570* |
| Male | 19 | 130.5 (43.9) | 121.1 | 79.2 - 224.6 |
|
| Female | 12 | 133.6 (33.6) | 134.3 | 81.1 - 192.8 |
|
| Age |
|
|
|
| 0.667* |
| <10 years | 12 | 127.7 (35.6) | 122.1 | 79.2 - 207.3 |
|
| ≥10 years | 19 | 134.2 (42.8) | 123.2 | 81.1 - 224.6 |
|
| Length illness |
|
|
|
| 0.875† |
| <5 years | 6 | 135.7 (44.1) | 131 | 79.2 - 207.3 |
|
| 5 - 10 years | 10 | 129.6 (31.5) | 122.1 | 90.8 - 186.4 |
|
| >10 years | 15 | 131.5 (45) | 110.2 | 81.1 - 224.6 |
|
| Type of thalassemia |
|
|
|
| 0.066* |
| Major | 16 | 141.2(16.8) | 126.8 | 84.2 - 224.6 |
|
| Intermedia | 15 | 121.6 (36.8) | 110.2 | 79.2 - 207.3 |
|
| Thalassemia degrees |
|
|
|
| 0.386* |
| Moderate | 20 | 129.4 (42.9) | 113.3 | 79.2 - 224.6 |
|
| Severe | 21 | 135.8 (34.6) | 128.2 | 84.2 - 212 |
|
| Iron chelating agent |
|
|
|
| 0.240* |
| Deferiprone | 23 | 126.1 (36.7) | 116.4 | 79.2 - 212 |
|
| Deferasirox | 8 | 147.9 (45.9) | 147.3 | 84.2 - 224.6 |
|
| Treatment adherence |
|
|
|
| 0.217* |
| Optimal | 15 | 122.5 (33.7) | 123.2 | 79.2 - 105.1 |
|
| Not optimal | 16 | 140.3 (43.8) | 122.1 | 56.7 - 112 |
|